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Abstract
Background: Pancreatic cancer (PDAC) is characterized by an abundant fibrous tissue rich in Tenascin-C (TNC), a large ECM
glycoprotein mainly synthesized by pancreatic stellate cells (PSCs). In human pancreatic tissues, TNC expression increases in
the progression from low-grade precursor lesions to invasive cancer. Aim of this study was the functional characterization of
the effects of TNC on biologic relevant properties of pancreatic cancer cells.
Methods: Proliferation, migration and adhesion assays were performed on pancreatic cancer cell lines treated with TNC or
grown on a TNC-rich matrix. Stable transfectants expressing the large TNC splice variant were generated to test the effects
of endogenous TNC. TNC-dependent integrin signaling was investigated by immunoblotting, immunofluorescence and
pharmacological inhibition.
Results: Endogenous TNC promoted pancreatic cancer cell growth and migration. A TNC-rich matrix also enhanced
migration as well as the adhesion to the uncoated growth surface of poorly differentiated cell lines. In contrast, adhesion to
fibronectin was significantly decreased in the presence of TNC. The effects of TNC on cell adhesion were paralleled by
changes in the activation state of paxillin and Akt.
Conclusion: TNC affects proliferation, migration and adhesion of poorly differentiated pancreatic cancer cell lines and might
therefore play a role in PDAC spreading and metastasis in vivo.
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Introduction
Pancreatic ductal adenocarcinoma (PDAC) represents 85–90%
of all pancreatic neoplasms. In 2010 43,140 people in the US were
estimated to be diagnosed with pancreatic cancer and 36,800 to
die of this lethal disease, making PDAC the fourth most common
cause of tumor-related mortality in spite of an incidence of only
3% of total cases [1]. PDAC survival rates improved only
marginally in the last 30 years and PDAC patients still have a
very poor prognosis, with an overall 5-year survival rate below 5%
and a median survival rate that ranges from 2 months in patients
with metastatic disease to 8 months in patients with non-metastatic
disease at the time of diagnosis [2]. PDAC outcomes did not
change much in the last several years mainly because of late
diagnosis. PDAC as localized and regional disease is mainly
asymptomatic and tools for an early detection are still missing.
Once diagnosed, pancreatic cancer is often refractory to any
chemotherapy and radiotherapy treatment, and many clinical
trials have failed to demonstrate a significant improvement in
overall survival during the last decade [3]. Therefore, a better
comprehension of the mechanisms involved in PDAC develop-
ment, maintenance and spreading is needed to develop new
targeted therapies for the treatment of this nowadays still fatal
disease.
A characteristic feature of PDAC is the so-called ‘‘desmoplastic’’
reaction, an abundant fibrous tissue that surrounds cancer cells
and mainly consists of blood vessels and stromal cells spread in a
scaffold of extracellular matrix (ECM). The development of the
desmoplastic reaction is mainly due to pancreatic stellate cells
(PSCs). PSCs are stromal cells which, after conversion from a
quiescent into an active myofibroblast-like phenotype, secrete
ECM proteins and matrix degrading enzymes, thus establishing an
environment that strongly promotes cancer progression and, at the
same time, imposes a barrier to drug delivery [4–7].
Tenascin-C (TNC) is a large ECM glycoprotein composed of six
monomers linked at their N-termini with disulfide bonds to form a
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structural motifs arranged in a linear order, including between 8
and 15 fibronectin type III (FN-III)-like repeats [8,9]. The
alternative splicing of the FN-III-like repeats is able to modulate
the biological function of TNC by modifying its interaction with
other ECM proteins, like fibronectin (FN), or with cell surface
receptors, like integrins or annexin II, and by conferring
sometimes opposite roles to TNC in cell spreading, adhesion
and proliferation [10,11].
TNC is mainly expressed duringe m b r y o n i cd e v e l o p m e n t .I n
adults, TNC has a limited pattern of expression (in the
basement membrane of the skin, in the ducts of the salivary
glands, in the colon mucosa and in the vessel walls of different
organs), but protein levels rise dramatically under various
physiological and pathological conditions, such as tissue
remodeling, neovascularisation and inflammation [12,13].
Moreover, most solid tumors express high levels of TNC.
TNC is able to influence cancer growth by affecting cell
adhesion and motility in a way that can promote invasion and
metastasis [14] and by influencing the cellular expression of
tumor suppressor genes, oncogenes and genes involved in the
maintenance of genome stability [15]. In the normal pancreas,
TNC is expressed in the muscle wall of blood vessels and in the
stromal tissue around the interlobular ducts. TNC expression is
up-regulated in acute and chronic pancreatitis [16], and
increases in the progression from low-grade precursor lesions
(pancreatic intraepithelial neoplasia, PanIN) to PDAC [17]. In
PDAC TNC is exclusively expressed in the stroma around the
neoplastic glands [16,17]. Up-regulation of TNC in cancer
progression seems to involve specifically the large splice variant,
as the largest TNC transcript, corresponding to the unspliced
form of TNC, is found in pancreatic cancer and in chronic
pancreatitis, but not in the normal pancreas [17]. PSCs have
been shown to be the main source of TNC in vivo, whereas
PDAC cells did not show any expression of TNC either by
immunohistochemistry or immunoblotting. However, low levels
of TNC mRNA were found in pancreatic cancer cell lines by
real-time quantitative PCR [17].
In this study, we performed an extensive analysis of the effects of
exogenous TNC on pancreatic cancer cell functions and we
investigated the effect of endogenous TNC overexpression in the
pancreatic cancer cell line PANC-1. Our results point to a main
role of TNC in the regulation of the interactions between epithelial
cells and ECM in the progression of pancreatic cancer.
Results
Effects of exogenous TNC on pancreatic cancer cell
growth
At first, it was tested if TNC added to the culture medium at
different concentrations could affect cell viability. An increase in
the number of viable Capan-1, AsPC-1 and SU.86.86 cells (up to
25%) at TNC concentration of 0.01–0.1 mg/ml was observed, as
measured with the MTT assay after 72 hours of growth in serum
free medium (Fig. 1A). Growth of AsPC-1 and Capan-1 was
inhibited at the highest TNC concentration (10 mg/ml, 41 and
34% decrease, respectively). TNC had an inhibitory effect on the
viability of the PANC-1 and MIA PaCa-2 cell lines (Fig. 1A). Since
TNC exerts its function as an ECM-protein, cells were grown on a
TNC-rich matrix. When seeded on TNC-coated plates and grown
up to 72 hours in serum-free medium, PANC-1 and MIA PaCa-2
showed a 44% and 27% increase in viability, respectively, whereas
the growth of Capan-1 and AsPC-1 decreased (23% and 45%,
respectively) (Fig. 1B).
Exogenous TNC modulates the motility of pancreatic
cancer cell lines
In order to test the effect of TNC on the migration of pancreatic
cancer cell lines, wound healing assays were performed maintain-
ing the cells in serum free medium in order to minimize cell
proliferation. TNC had no effect on the wound closure when
added to the growth medium (Fig. 2A). When grown on a TNC-
rich matrix, pancreatic cancer cells closed the wound in a dose-
dependent way, but each cell line displayed a quite individual
response to different concentrations of TNC. In detail, cell
migration increased up to 1.7 and 1.1-fold in the SU.86.86 and
PANC-1 cell lines, respectively, reaching statistical significance at
a TNC concentration of 0.5 mg/cm2 in SU.86.86 cells and of
0.1 mg/cm2 in PANC-1 cells. On the other hand, the wound
closure decreased significantly (up to 0.8-fold) in Capan-1 cells
with TNC concentrations of 0.5 and 2.5 mg/cm2 (Fig. 2B). A
TNC concentration of 2.5 mg/cm2 had toxic effects on the
PANC-1 cells, and the wound healing assay could not be
performed under this condition.
Effects of endogenous TNC on cell viability and migration
To give further support to the observed promoting effects of TNC
on pancreatic cancer cell growth and motility in the coating
procedure, PANC-1 cells were used to generate stable transfectants
expressing the large TNC splice variant. Since TNC physiologically
acts as an extracellular protein, positive clones were further selected
on the basis of their capability to secrete TNC in the culture medium.
As shown in figure 3A, the expression levels of secreted TNC were
quite different among positive clones. Different expression levels
reflected on some of the biological activities of TNC, such as its
capability to affect cell viability. In fact, the number of viable cells, as
measured with the MTT method after 24, 48 and 72 hours of growth
in complete medium, was higher in the TNC-positive clones
compared both to the non transfected and to the mock transfected
PANC-1 cells (Fig. 3B and C). The strongest effect (compared to the
non transfected cells) was observed in the T2 clone, which also
showed the highest expression levels of secreted TNC (Fig. 3A and B).
I nd e t a i l ,i nc o m p a r i s o nw i t hn o nt r a n s f e c t e dc e l l s ,P A N C - T 2c e l l s
showed an increase in cell viability of 2.06-fold +/20.01 after
24 hours, of 2.49-fold +/20.04 after 48 hours and of 3.88+/20.09
after 72 hours. In PANC-T24 the increase was of 1.21-fold +/20.01
after 24 hours and of 1.14-fold +/20.02 after 48 hours, and in
PANC-T27 of 1.43-fold +/20.02 after 24 hours, of 1.32-fold +/
20.03 after 48 hours and 1.08-fold +/20.05 after 72 hours. The cell
viability rates of PANC-1 cells overexpressing TNC compared to the
mock transfected cells were 55% higher at 24 hours, 68% higher at
48 hours and 99% higher at 72 hours (Fig. 3C).
Cell migration on the other hand was not influenced by the
expression levels of secreted TNC. Stable transfected PANC-T2,
PANC-T24 and PANC-T27 cells closed the wound faster than
non transfected and mock transfected cells. When compared to
the non transfected PANC-1 cells, this effect was significant at
24 hours (1.52-fold +/20.09) and at 48 hours (1.46-fold +/
20.08) for PANC-T2 and at 24 (1.66-fold +/20.13) and
48 hours (1.46-fold +/20.08) for PANC-T27 (Fig. 3D). All
positive clones together had a higher migration rate in
comparison to the mock transfected clones (62% at 24 hours
and 43% at 48 hours, Fig. 3E).
Exogenous TNC stimulates cell adhesion on uncoated
plates and reduces cell spreading on FN
As cell adhesion together with migration and invasiveness is a
critical step involved in cancer spreading and metastasis, the
Tenascin-C in Pancreatic Cancer Progression
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investigated. Since TNC overexpression correlates with poor
tumor differentiation in vivo [16], we focused our study on the
poorly differentiated cell lines PANC-1 and SU.86.86 [18,19].
TNC coating strongly enhanced the adhesion of both cell lines
(PANC-1: 7.0-fold, p,0.001; SU.86.86: 4.6-fold, p,0.001) as
estimated by crystal violet absorbance spectroscopy of attached
cells (Fig. 4A, left panel). In the tissue context, cells interact with
TNC in combination with other ECM proteins. Among these, FN
is often co-expressed with TNC [20]. Therefore, in order to test if
TNC modulates cell adhesion in the presence of FN, PANC-1 and
SU.86.86 cells were plated on a mixed substrate of FN and TNC.
TNC presence determined a significant decrease in the attachment
of both cell lines to FN at 3 hours after plating (PANC-1: 1.6-fold,
p,0.001; SU.86.86: 1.2 fold, p=0.003) (Fig. 4A, left panel). To
test if this effect could be due to substrate competition between the
two proteins when used together to coat the plastic surface, the
substrate binding efficiency of the composite matrix was
investigated by ELISA. The binding efficiency of FN or TNC
alone was not affected when the plates were coated with both
proteins simultaneously, as shown in figure 4B and C. Cell viability
was also not significantly affected when cells were grown onto FN/
TNC coated plates compared with FN coated plates (MTT assay,
data not shown). Taken together, these results show that TNC
interferes with cell adhesion on FN, but it has an opposite effect on
uncoated plates.
TNC and FN influence paxillin and Akt activation by
phosphorylation
In order to investigate the pathways involved in the adhesive
behavior of pancreatic cancer cells on TNC and/or on FN
substrates, the phosphorylation level of paxillin at Tyr 118, an
early step in integrin mediated signaling, as well as the
phosphorylation level of Akt at Ser 473 and the expression levels
of vinculin, a protein involved in the connection of focal adhesions
to the actin cytoskeleton, were analyzed by immunoblotting.
Figure 1. Effects of exogenous TNC on pancreatic cancer cell growth. (A) Cells were grown for 72 hours in serum free medium containing
different concentrations of TNC (0.01, 0.1, 1 and 10 mg/ml). (B) Cells were grown for 72 hours in serum free medium onto TNC coated plates (1 mg/
cm
2). Growth was determined with MTT assay. Data are calculated as mean +/2 s.e.m. of three experiments and are expressed as percentage
compared to the untreated controls (up,0.05, *p,0.01, **p,0.001, Students two-tailed t test).
doi:10.1371/journal.pone.0021684.g001
Figure 2. Effect of TNC on the migration of pancreatic cancer cell lines. (A)Cells were plated onto uncoated plates and after 24 hours the
monolayer was scraped with a 10 ml pipette tip. Cells were then incubated in serum free medium or in medium with the addition of TNC at different
concentrations (0.2 mg/ml, 1 mg/ml and 5 mg/ml) up to 48 hours. (B) Cells were plated onto 24-well plates coated with three different concentrations
of TNC (0.1 mg/cm
2, 0.5 mg/cm
2 and 2.5 mg/cm
2) or onto uncoated plates and after 24 hours the monolayer was scraped with a 10 ml pipette tip. Cells
were then incubated in serum free medium up to 48 hours. Migration of cells into wounded areas was evaluated counting migrated cells manually
and by the TScratch software [36] and a total of 2–8 fields were counted per group in each experiment. Data are calculated as mean +/2 s.e.m. and
expressed as fold-change compared to the non treated cells (up,0.05, *p,0.01, **p,0.001, Students two-tailed t test).
doi:10.1371/journal.pone.0021684.g002
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on the phosphorylation state of Aktin the PANC-1 and SU.86.86
cell lines during the first steps of cell adhesion (45 min). This effect
was not evident anymore after 24 hours and at later time points
(not shown). As for cell adhesion, TNC seemed to have opposite
effects depending on the experimental set up. In fact phospho-Akt
was slightly up-regulated when comparing TNC coated plates vs
uncoated plates and down-regulated when comparing FN/TNC
Figure 3. Effects of endogenous TNC on cell proliferation and migration. PANC-1 cells were stably transfected with a vector driving the
expression of large TNC (PANC-T2, PANC-T24 and PANC-T27 cells) and with the empty vector (PANC-C21, PANC-C23 and PANC-C27 cells). (A)
Immunoblotting of precipitated cell culture medium of the transfected PANC-1 cells grown up to 80% confluence. To ensure that a comparable
number of transfected cells was the source of secreted TNC, GAPDH expression in whole cell extracts was tested. PANC-T2 cells show the highest
levels of secreted TNC, while lower levels are observed in PANC-T24 and PANC-T27. The control clones in comparison do not show any TNC secretion.
(B) Cells were grown in complete medium. Growth was determined with MTT assay at different time points (24, 48 and 72 hours). Data are calculated
as mean +/2 s.e.m. of three experiments and are expressed as percentage compared to the PANC-1 cells (up,0.05, *p,0.01, **p,0.001, Students
two-tailed t test). The proliferation rate is significantly higher for PANC-T2 at all time points (p,0.001), for PANC-T24 at 24 hours (p,0.001) and at
48 hours (p=0.022) and for PANC-T27 at 24 (p,0.001) and 48 hours (p=0.009). (C) The proliferation of all the PANC-1 positive clones (PT) compared
to the mock transfected cells (PC) is significantly higher for each tested time point (24 hours: p=0.004, 48 hours: p=0.012, 72 hours: p=0.026) (D)
Transfected PANC-1 cells were plated, after 24 hours medium was changed with medium containing 0.1% FBS and, after overnight incubation, the
monolayer was scraped with a 10 ml pipette tip. Data are calculated as described in B. In comparison to the non transfected PANC-1 cells, migration is
significantly faster for PANC-T2 (p,0.001 at both time points) and for PANC-T27 (p=0.042 at 24 hours; p=0.009 at 48 hours). (E) All together, the
PANC-1 positive clones (PT) migrate significantly faster compared to the mock transfected cells (PC) at both time points (p,0.001).
doi:10.1371/journal.pone.0021684.g003
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containing 1% FBS, incubated for 3 hours and fixed. For pharmacological inhibition, cells were incubated with AZD0530 2 mM for 15 min before
plating. Left panel: TNC enhances cell adhesion compared to uncoated plates and decreases cell attachment to FN. Right panel: When treated with
AZD0530, cells displayed a reduced adhesion compared to the non treated cells at all conditions tested. Data are calculated as mean +/2 s.e.m of two
experiments and expressed as fold-change compared to the control (Ctrl) (left panel) or to the untreated cells (right panel) (*p,0.01, **p,0.001,
ANOVA test). (B, C) 96-well plates were coated with TNC (0.5 mg/cm
2), FN (1 mg/cm
2) or both proteins simultaneously (FN/TNC) and ELISA was
performed as described in Methods. The substrate binding activity of TNC or FN is not affected when both proteins areused to coat the plastic
surface. (D, E) PANC-1 (D) and SU.86.86 cells (E) were plated for 45 min before total protein extraction was performed. Phosphorylation of paxillin at
Tyr 118 (pPAX) and of Akt at Ser 473 (pAKT), and total paxillin and Akt expression levels were investigated by immunoblotting using specific
antibodies and after treating the cells with the Src kinase inhibitor AZD0530. GAPDH detection was used to confirm equal protein loading.
doi:10.1371/journal.pone.0021684.g004
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when measuring paxillin activation, while vinculin levels were not
affected either by TNC or FN (not shown). The Src kinase
inhibitor AZD0530 (Saracatinib), which inhibits the phosphory-
lation of paxillin and Akt, was used to confirm that the observed
effects on cell adhesion were actually mediated by molecules of the
integrin signaling pathway. In adhesion experiments, after
incubation with AZD0530 an inhibition of paxillin and Akt
phosphorylation was observed (Fig. 4D and E). This effect was
accompanied by a significant decrease in PANC-1 and SU.86.86
adhesion at all conditions tested (PANC-1 FN: p=0.004; all other
conditions p,0.001), with the exception of SU.86.86 adhesion to
uncoated plates (Fig. 4A, right panel).
Next, TNC effect on focal adhesion assembly was investigated
on a morphological level by immunofluorescence. As shown in
Fig. 5, PANC-1 cells grown for 45 min on a TNC coated surface
showed a more diffuse co-localization pattern of vinculin and
phospho-paxillin than that observed on the uncoated surface,
where focal adhesions appeared more elongated and mainly
concentrated at the periphery of the spreading cell. On a FN
matrix, only slightly noticeable differences in phospho-paxillin and
vinculin distribution between cells adhered on FN and FN/TNC
were observed. In both cases, phospho-paxillin/vinculin areas
were mainly restricted to the periphery of the adhering cells, with
longer and more dispersed adhesion sites in the presence of TNC.
Discussion
PDAC is characterized by a prominent increase in the
connective tissue that surrounds cancer cells. Major contributors
to this so-called ‘‘desmoplastic’’ reaction are PSCs, a subpopula-
tion of pancreatic cells that, once activated by growth factors,
cytokines and oxidative stress, secrete excess amounts of ECM
proteins and soluble mediators establishing a cross-talk with tumor
cells. Several lines of evidence suggest that the desmoplastic
microenvironment plays a key role in regulating the rapid growth
and invasion of pancreatic cancer, angiogenesis and resistance to
chemotherapy [4–7,21–26].
TNC is a large stromal ECM protein that is up-regulated in the
progression from PanINs to PDAC [17] and its expression has
been correlated with a poorly differentiated phenotype of PDAC
[16]. Moreover, TNC expression has been correlated with a poor
prognosis of patients affected by lung and brain cancer [21,27–29],
whereas no correlation between expression levels and prognosis
has been found in pancreatic cancer [16]. TNC is able to interact
with several ECM proteins (such as FN, perlecan, aggrecan,
versican and brevican) and many cell-surface receptors (including
integrins a2b1, a7b1, a9b1, avb3, annexin II, EGFR and
syndecan 4), modulating cellular signaling and influencing cell
migration and proliferation [11]. Additionally, in the adult
organism TNC has adhesive and anti-adhesive properties and is
expressed during physiological and pathological conditions where
cell migration and tissue remodeling is involved, like in the wound
healing process or during tumorigenesis and metastasis [11].
However, the molecular mechanisms by which TNC influences
cancer progression are still largely unknown. To address this
question in PDAC, we have investigated how TNC affects biologic
relevant properties of pancreatic cancer cells.
The results presented here demonstrate that TNC is able to
support and promote growth and migration of poorly differenti-
ated pancreatic cancer cell lines. Another interesting observation is
that TNC alone shows a pro-adhesive effect on pancreatic cancer
cells, in contrast to the reported anti-adhesive effect in the majority
of other studied cell lines, like glioblastoma and breast carcinoma
cells [22]. This pro-adhesive effect on pancreatic cancer cells is
associated with an increase in the phosphorylation state of Akt and
to a lesser extent of paxillin. This suggests a mechanism involving
integrin-mediated adhesion to TNC, in analogy to what has been
Figure 5. Cellular distribution of phospho-paxillin and vinculin proteins on coated surfaces. PANC-1 cells were let adhere to uncoated or
TNC, FN and FN/TNC coated coverslips for 45 min, gently washed, fixed and stained using fluorescent secondary antibodies. Focal adhesion plaques
were evidenced by co-localization of vinculin (green) and phospho-paxillin (pPAX, red). Cell nuclei were counterstained with Hoechst 33342.
doi:10.1371/journal.pone.0021684.g005
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increase of Ser 473 phosphorylation of Akt in cells adhering to
TNC promotes cell survival in serum deprived medium [23].
However, the effects of TNC on pancreatic cancer cell viability
and proliferation were quite heterogeneous and an inhibition of
the growth was observed in some cell lines, mostly at the highest
concentrations of TNC. This result is not surprising, due to the
heterogeneity of PDAC cell lines concerning their origin and
differentiation [19,20] and to the pleiotropic and often opposite
effects of TNC depending on the cell and tissue context. In vitro
studies often report contradictory results, with TNC both
stimulating [24] and inhibiting [25] cell growth and promoting
both cell adhesion and detachment [26]. Moreover, opposite
adhesive and migratory responses to TNC in the same glioma cell
line depending on the integrin receptor involved [30] and different
adhesive responses mediated by the same integrin in different cell
lines [31] have been described. Interestingly, on a FN coated
surface TNC decreases pancreatic cancer cell adhesion and
phospho-paxillin and phospho-Akt levels. This effect on a mixed
TNC-FN matrix, which closely resembles the in vivo situation,
where TNC and FN interact in the tumor-associated ECM, has
already been described for glioblastoma and breast carcinoma cells
[20,22]. In these tumors, TNC reduces cell spreading on FN
interfering with FN binding to the integrin co-receptor syndecan-
4, thus compromising focal contact and stress fiber formation [29].
Since the substrate binding efficiency of FN was not affected by
TNC in our study, as assessed by ELISA, a similar mechanism of
competition for cell surface receptors can be hypothesized in
PDAC cells. Due to this effect, activation of paxillin and focal
adhesion kinase (FAK) and, consequently, actin stress fiber and
focal contact formation as well as full cell spreading is inhibited,
with an overall enhancement in cell proliferation [22]. Weak
binding to FN usually correlates with an enhanced proliferation in
many tumor cells [32]. In our experimental set up, we did not
observe an increase in cell proliferation for PANC-1 and SU.86.86
cells on a mixed substrate of FN and TNC compared to FN alone,
probably because the effects of TNC on adhesion were limited to
short times (3 hours) and focal adhesion assembly in the FN-
adherent cells was only slightly altered by TNC, as observed by
immunofluorescence. These observations suggest that the mech-
anisms by which TNC influences cancer cell adhesion and
proliferation on a FN substrate are not general but strictly
dependent on the specific cell line and on the experimental set up
used.
It is known that the ability of cancer cells to interact with
extracellular matrix proteins, like FN, is crucial for cell invasion
and migration. Our data show that the number of pancreatic
cancer cells that adhere to FN at short times is decreased in the
presence of TNC but is still high and in the range of the number of
cells adhering to TNC alone. TNC may therefore act as a
modulator of early migratory events, which include substrate
sensing and adhesion, and may promote cell migration by
reducing cell adhesiveness to FN, thus inducing a more dynamic
interaction between the tumor cell and the ECM components.
Further work is needed to understand how TNC affects the
adhesion process during pancreatic cancer cell interaction with
FN, which cell receptors are involved and which additional
intracellular pathways may be altered.
In conclusion, the present data show that TNC affects growth,
motility and adhesion of pancreatic cancer cells, these effects being
divergent depending on cell differentiation and on the composition
of the extracellular matrix. Therapeutic strategies aiming at
disrupting the TNC-rich matrix might be therefore helpful in
contrasting the extraordinary aggressiveness of PDAC.
Materials and Methods
Maintenance of cell lines
Pancreatic cells of lines Capan-1, AsPC-1, PANC-1, MIA
PaCa-2 and SU.86.86 [18,19,33] (American Type Culture
Collection, ATCC) were maintained in high glucose DMEM
media containing 10% fetal bovine serum (FBS), and 1 X
Penicilline/Streptomicine (Invitrogen, Carlsbad, CA) at 37uCi na
humified atmosphere with 5% CO2. Cells were tested for
mycoplasma contamination by polymerase chain reaction (TA-
KARA, Shiga, Japan).
Generation of stable clones overexpressing TNC
The plasmid TNC-L, in which the large, unspliced isoform of
TNC is cloned into a pCMV-Script vector (Stratagene, La Jolla,
CA, USA), was a generous gift from Dr. JH Pringle (Department
of Cancer Studies & Molecular Medicine, University of Leicester
School of Medicine, UK) [34]. The complete TNC-L coding
sequence was checked by sequencing. Then, the TNC-L plasmid
and the empty vector pCMV-Script were first linearized with the
restriction enzyme APA-L1 and then transfected into the PANC-1
cancer cells using the FuGENE transfection reagent (Roche
Diagnostics, Mannheim, Germany), according to the manufactur-
er’s instructions. After 2 days, cells were subjected to G418
selection at a concentration of 1 mg/ml. After 2 weeks in the
presence of G418, several colonies were observed and amplified.
Colonies were checked for the presence of the transfected gene by
PCR assay using the primers 5-CGTGTACGGTGG-
GAGGTCTA-3 (on pCMV-Script) and 5-GACAC-
CAGGTTCTCCAGCTC-3 (in the TNC gene). The capability
of PCR-positive colonies to secrete TNC was confirmed by
Western blotting. The positive clones PANC-T2, PANC-T24,
PANC-T27 and the control (mock transfected) clones PANC-C21,
PANC-C23, PANC-C27 were selected for the following experi-
ments.
TNC and FN coating
TNC was purchased from Millipore (Millipore GmbH,
Schwalbach, Germany) and FN from Biochrom (Berlin, Ger-
many). For 96-well plates (viability and adhesion), coating was
performed with TNC at a final concentration of 1 mg/cm2. For
24-well plates (wound healing assays) TNC concentrations of
0.1 mg/cm2, 0.5 mg/cm2 and 2.5 mg/cm2 were used. For 6-well
plates (immunoblotting) a concentration of 0.5 mg/cm2 was used.
FN coating was performed with a final concentration of 2 mg/cm2
for 96-well plates and 1 mg/cm2 for 24- and 6-well plates. Coating
proteins were allowed to be adsorbed overnight at 4uC, wells were
then washed with PBS to remove unbound proteins and blocked
for 30 min at 37uC by the addition of 0.2% heat-denatured (85uC
for 12 min) BSA in PBS. Plates were finally washed twice with
sterile PBS and sterilized by UV exposure for 20 min. Coverslips
used in immunofluorescence experiments were placed into 24-
multi-well plates and coated in the same way. Mixed substrates of
TNC and FN were prepared by coating with both proteins
simultaneously. Uncoated plates, blocked with BSA, are referred
in this manuscript as ‘‘uncoated’’.
Growth assay
Cells were seeded into 96-multi-well plates (Nunc GmbH & Co.
KG, Langenselbold, Germany) at a density of 20,000/cm2 and in
medium containing 10% FBS. After 24 hours the medium was
changed with serum free medium containing different concentra-
tions of TNC (0.01, 0.1, 1 and 10 mg/ml). Cells were then grown
for 72 hours before 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetra-
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described [35]. To test the effect of TNC coating, cells from 70–
80% confluent cultures were seeded into 96-multi-well plates at a
density of 20,000/cm2 in serum-free medium. Cells were then
grown up to 72 hours and MTT assay was performed. For
experiments with stably transfected PANC-1, cells were seeded
into 96-multi-well plates at a density of 10,000/cm2 and in
medium containing 10% FBS. Cells were then grown up to
72 hours and MTT assay was performed at different time points
(24, 48 and 72 hours).
Adhesion assay
Cells were trypsinized, resuspended to a concentration of
300,000/ml in medium with 1% FBS and incubated 20 min at
37uC, 5% CO2. For experiment with the Src kinase inhibitor
AZD0530 (Saracatinib), cells were further incubated with the drug
(2 mM) for 15 min. Then, 50 ml (15,000 cells) were plated onto 96-
multi-well plates, whose wells had been filled with 50 ml medium
containing 1% FBS and equilibrated at 37uC, 5% CO2 for
1 hour. After 3–24 hours of incubation, medium was aspirated
and the wells were washed twice with PBS to remove non-
adherent cells. Cells were then fixed with 5% glutaraldehyde in
PBS for 20 min and stained for 60 min with a filtered solution of
0.1% (w/v) crystal violet in 200 mM 2-(N-morpholino)ethanesul-
fonic acid (MES), pH 6.0. Cells were washed four times with
water, air-dried and lysed in 100 ml of 10% (v/v) acetic acid in
water. Absorption was measured at 560 nm using an ELISA
reader. Six-well plates were used for protein extraction. Both
adherent and non-adherent cells were collected after 45 min–
72 hours of incubation.
Wound healing assay
Cells were plated onto 24-multi-well plates and after 24 hours
the monolayer was scraped with a 10 ml pipette tip. After three
washes with PBS, cells were incubated at 37uC, 5% CO2, in serum
free medium with different TNC concentrations (0.2 mg/ml, 1 mg/
ml and 5 mg/ml) or without TNC. To test the effect of TNC
coating, the same procedure was performed on TNC-coated 24-
multi-well plates (0.1 mg/cm2, 0.5 mg/cm2 and 2.5 mg/cm2 TNC,
respectively). In both cases, the migration of cells into wounded
areas was evaluated at the indicated times by taking images with a
Zeiss Axiovert microscope coupled with a digital camera
(AxioCam ICc3, Carl Zeiss Vision GmbH, Jena, Germany) and
counting migrated cells manually. A total of 2–4 fields were
counted per group in each experiment.
For experiments with stably transfected cells, cells were plated
onto 24-multi-well plates at a density of 75,000 cells/cm2 and,
after 6 hours, medium was changed and cells were maintained
overnight in medium containing 0.1% FBS. The monolayer was
then scraped with a 10 ml pipette tip. After three washes with PBS,
cells were incubated at 37uC, 5% CO2, in medium completed
with 0.1% FBS. Images were taken at the indicated times with a
Evos XL microscope (AMG - Advanced Microscopy Group,
Bothell, WA, USA) and cell migration into wounded areas was
evaluated using TScratch software [36]. A total of 4–8 fields were
counted per group in each experiment.
Whole cell extract and supernatant preparation
Culture medium was removed and not attached cells were
collected by centrifugation. Cell monolayers were rinsed twice
with cold PBS. Both pelleted and still adherent cells were lysed in
cold lysis buffer (20 mM Tris, 150 mM NaCl, 1% NP-40, 0.5%
sodium deoxycholate, 1 mM EDTA, 1 mM EGTA pH 7.4)
supplemented with protease and phosphatase inhibitor cocktails
(Roche Diagnostics, Mannheim, Germany). Cell lysates were
passed through a 26G needle several times and cellular debris was
removed by centrifugation at 150006g for 10 min at 4uC. The
protein concentration in the soluble fractions was determined
using the BCA protein assay kit (Thermo Scientific, Schwerte,
Germany) and the extracts were aliquoted and stored at 280uC.
Transfected cell lines were grown in culture medium for 72 hours
until cells reached 80% confluence. 250 ml of the supernatant were
then taken and precipitated with 4 vol acetone over night at
220uC. The precipitate was centrifuged 20 min at 13.000 rpm
and resuspended in 2X Laemmli buffer.
Immunoblot analysis
Cell lysates were subjected to SDS-PAGE with 5%, 10% or
12% polyacrylamide gels using the Mini-PROTEAN Tetra cell
apparatus (Bio-Rad Laboratories GmbH, Munich, Germany) at
110 V for 1 hour in Tris–glycine buffer (25 mM Tris, 250 mM
Glycine, 0.1% SDS, pH 8.3). Resolved proteins were transferred
from the gels to nitrocellulose membranes using a Mini Trans-
Blot Cell electrophoretic transfer cell (Bio-Rad) at 120 V in
transfer buffer (48 mM Tris, 39 mM Glycine, 0.025% SDS, 20%
Methanol, pH 8.3). Non-specific antibody binding was blocked
by incubation of the membranes in 5% BSA in TTBS buffer
(20 mM Tris, 136 mM NaCl, 0.1% Tween20, pH 6,8), for
1 hour at room temperature. The membranes were then
incubated overnight at 4uC with antibodies anti-phospho-paxillin
(Tyr 118, 1:1000, GeneTex Inc.), anti-paxillin (1:500, Cell
Signaling), anti-GAPDH (1:1000, Santa Cruz Biotechnology),
anti-vinculin (1:1000, Sigma-Aldrich), anti-phospho-Akt (Ser 473,
1:1000, Cell Signaling), anti-Akt (1:1000, Cell Signaling) diluted
in TTBS with 3% BSA. After three washes in TTBS, membranes
were then probed for 1 hour at room temperature with
horseradish peroxidase-conjugated secondary antibodies (anti-
mouse or anti-rabbit-IgG, Sigma-Aldrich) diluted 1:2000 in
TTBS with 5% blotting-grade milk, and then washed again
three times with TTBS. All steps were performed under gentle
agitation on a rotary shaker. The signals were visualized using the
Super Signal West Pico Chemiluminescent Kit (Thermo
Scientific, Schwerte, Germany) and by light-sensitive imaging
film (Amersham Hyperfilm ECL, GE Healthcare, Munich,
Germany).
Immunofluorescence
Cells adhering to coverslips were washed with PBS, fixed with
4% formaldehyde in PBS buffer for 15 min at RT, washed three
times with TBS (50 mM Tris, 138 mM NaCl, 2.7 mM KCl,
pH 7,6), permeabilized with Triton X-100 (0.25% v/v in TBS) for
5 min, before being washed twice and blocked for 1 hour in
blocking solution (TBS containing 10% goat serum and 0.1%
Triton X-100). Then, incubation with antibodies anti-phospho-
paxillin (Tyr 118, 1:100, Santa Cruz Biotechnology, CA) and anti-
vinculin (1:200) was performed in the blocking solution at RT in a
humidified chamber overnight. After washing three times with
TBS, slides were incubated with Alexa Fluor 488 goat anti-mouse-
IgG or Alexa Fluor 647 goat anti-rabbit-IgG (1:200, Invitrogen
GmbH, Karlsruhe, Germany) in blocking solution for 1 hour.
Slides were then washed again three times before being
counterstained with Hoechst 33342 (0.2 mg/ml in water) for
5 min, briefly washed with TBS, covered with anti-fade mounting
medium (Vectashield, Loerrach, Germany) and placed onto
microscope slides. Slides were examined under a Zeiss Axiovert
fluorescence microscope (Carl Zeiss AG, Germany). Negative
controls were performed omitting the primary antibodies.
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96-well plates were coated with TNC (0.5 mg/cm2), FN (1 mg/
cm2) or both proteins simultaneously (FN/TNC). A calibration
curve was generated using FN at a density between 125 ng/cm2
and 2 mg/cm2 and TNC at a density between 62.5 ng/cm2 and
1 mg/cm2 to coat the plate.The amount of FN or TNC on the
plate was then quantified by the ELISA assay (IBL International
GmbH, Hamburg, Germany) according to the manufacturer’s
instructions.
Statistical analysis
Means were compared using the Students t-test or the one-way
analysis of variance (ANOVA) with the package S-PLUS (Tibco,
Palo Alto, CA). Data are presented as mean 6 SEM (standard
error of the mean).
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